<?xml version="1.0" encoding="UTF-8"?>
<p>Remdesivir received EUA by FDA last week for use in patients hospitalized with COVID-19 based on a clinical trial, which showed remdesivir, accelerated the recovery time by 31%, from 15 days to 11 days in patients who received treatment with it. It reduced the mortality from 11% to 8%, but it was not statistically significant [
 <xref rid="R28" ref-type="bibr">28</xref>]. Few case reports and series suggesting its effectiveness in the novel COVID-19 has been published [
 <xref rid="R29" ref-type="bibr">29</xref>]. Notable side effects are nausea, vomiting, and reversible rise in aspartate aminotransferase and alanine transaminase.
</p>
